Abstract
Heart failure due to dilated cardiomyopathy is associated with a significant increase in risk of thromboembolism. The incidence can be estimated, on the average, at 2.0-2.5 events per 100 patients per year. At this time, in the absence of randomized trials, limited evidence exists to support the use of anticoagulant treatment for patients with heart failure due to dilated cardiomyopathy in sinus rhythm, even if these subjects appear to be at higher risk than those with ischemic cardiomyopathy and comparable degree of left ventricular dysfunction. Women with left ventricular ejection fraction
| Translated title of the contribution | Anticoagulant treatment in patients with dilated cardiomyopathy |
|---|---|
| Original language | Italian |
| Pages (from-to) | 227-232 |
| Number of pages | 6 |
| Journal | Annali Italiani di Medicina Interna |
| Volume | 13 |
| Issue number | 4 |
| Publication status | Published - 1998 |
ASJC Scopus subject areas
- Internal Medicine